Education
About Us
Working with TipRanks
Follow Us
NeuroOne Medical Technologies (NMTC)
NASDAQ:NMTC
RESEARCH TOOLSreports
Earnings Data
Report Date
Aug 08, 2025TBA Not Confirmed
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.05Last Year’s EPS
-0.1Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: -3.23%
|Next Earnings Date:Aug 08, 2025
Earnings Call Sentiment|Positive
The earnings call highlights a strong growth trajectory with significant increases in revenue and gross margins, successful capital raise, and positive clinical outcomes. However, there are challenges in maintaining revenue growth on a quarterly basis and the company continues to operate at a net loss, albeit improved. Overall, the company is well-positioned for future growth with new applications and strategic partnerships.Company Guidance
In the second quarter of fiscal year 2025, NeuroOne Medical Technologies provided guidance indicating a significant increase in product revenue and gross margins. The company expects product revenue to range between $8 million and $10 million, representing an increase of 132% to 190% over fiscal 2024. Product gross margins are anticipated to be between 47% and 51%, up from 31% in the previous year. This guidance excludes the $3 million upfront license payment received from Zimmer Biomet. NeuroOne has also bolstered its financial position with a successful capital raise, adding $8.2 million in net proceeds, and the company believes it is fully funded through at least fiscal 2026. The company remains debt-free and is focused on ramping revenues through strategic partnerships and expanding its product offerings, particularly in international markets.Strong Revenue Growth
Product revenue increased 97% to $4.7 million in the first half of fiscal 2025 compared to the same period in fiscal 2024.
Significant Improvement in Gross Margins
Product gross margins increased to 57.9% in the first half of fiscal 2025, more than doubling from the first half of fiscal 2024.
Successful Capital Raise
The company raised $8.2 million in net proceeds from a successful capital raise, ensuring funding through at least fiscal 2026.
Positive Clinical Outcomes
Majority of patients treated with the OneRF ablation system are now seizure free, with one patient being seizure free for almost an entire year.
Expansion into New Applications
Filed a 510(k) submission with the FDA for the OneRF trigeminal nerve ablation system ahead of schedule, with potential revenue generation by late 2025.
NMTC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NMTC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2025 | $0.62 | $0.64 | +3.23% |
Feb 12, 2025 | $1.09 | $1.12 | +2.75% |
Dec 17, 2024 | $0.76 | $0.79 | +3.95% |
Aug 14, 2024 | $0.74 | $0.73 | -1.35% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does NeuroOne Medical Technologies (NMTC) report earnings?
NeuroOne Medical Technologies (NMTC) is schdueled to report earning on Aug 08, 2025, TBA Not Confirmed.
What is NeuroOne Medical Technologies (NMTC) earnings time?
NeuroOne Medical Technologies (NMTC) earnings time is at Aug 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NMTC EPS forecast?
NMTC EPS forecast for the fiscal quarter 2025 (Q3) is -0.05.